drugset / Trial / NCT02988089
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
Phase 4
Unknown
480 enrolled
Shandong University
Binzhou People's Hospital · collabGeneral Hospital of Jinan Military Region · collabLiaocheng People's Hospital · collabShandong Provincial Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Timeline
- Start
- 2017-04-20
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Subject | Levofloxacin | Small molecule | — | — |
| Subject | Metronidazole | Small molecule | — | — |
| Subject | Tetracycline | Unknown | 750 mg | — |
| Subject | tinidazole | Small molecule | — | — |
| Background | Ilaprazole | Small molecule | 5 mg | — |
| Background | colloidal bismuth pectin | Unknown | 200 mg | — |